2 result(s) for
|PI Name||Protocol #||Title|
|Ronan Swords||STUDY00016492||Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia|
|Rebecca Silbermann||STUDY00018117||A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma|
You may also qualify for Phase 1 Program trials.
For more information: